Articles tagged with Monoclonal Antibodies
Researchers have developed a dual-targeting strategy to combat emerging infectious diseases. A fully human monoclonal antibody cocktail provides complete protection against lethal Nipah virus infection, even when treatment is given after infection has begun.
Researchers highlight the promise of using human monoclonal antibodies to treat patients more effectively and tackle antimicrobial resistance. mAbs can be designed to target only the disease-causing bacteria, thereby protecting the microbiome.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
A Phase I clinical trial of a human monoclonal antibody for Lyme disease demonstrates its safety, tolerability, and pharmacokinetics. The treatment, TNX-4800, provides lasting serum concentrations and has the potential to offer passive immunity against the disease.
Researchers from Chiba University found that antibody therapeutics with stronger Fcγ receptor binding are more likely to be recognized as foreign and associated with higher anaphylaxis risk. High affinities for Fcγ receptors critical determinants of anaphylaxis, study suggests.
Rice bioengineer Omid Veiseh has been awarded a $2.2 million grant to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods. The platform aims to reduce dosing frequency and improve access to biologic therapies in low- and middle-income countries.
A Phase III clinical trial found that over half of patients who received ianalumab for primary ITP maintained safe platelet counts without serious bleeding episodes for at least one year. The study suggests a new treatment option with the potential to improve long-term quality of life for patients.
A European study found that long-acting monoclonal antibody immunisation effectively prevented hospitalisation due to RSV infection among children under two years old. The overall immunisation effectiveness was 79%, with a decline in protection over time, highlighting the need for ongoing monitoring.
In response to rising RSV cases, ECDC advises policymakers and public health authorities on effective ways to mitigate the impact of RSV disease in infants. Immunisation interventions, including long-acting monoclonal antibodies and maternal vaccines, can prevent severe illness and hospitalization.
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
A new monoclonal antibody has shown dose-dependent full protection against the malaria parasite with minimal side effects. Researchers found that a single injection of the antibody could provide months-long protection, offering a fundamentally different way to prevent infection before it starts.
Researchers at UMC Utrecht discovered that converting monoclonal antibodies from IgG to IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. This finding could guide the future design of antibody therapies against bacterial infections.
Researchers have developed a tool that can predict how patients with multiple sclerosis will respond to natalizumab treatment, allowing for targeted treatments with fewer side effects. The tool uses high-content imaging and machine learning to analyze cell morphology and identify individuals who are unlikely to respond to the medication.
Researchers developed a novel label-free biosensing platform to monitor cellular secretion of monoclonal antibodies in real-time. This approach enables rapid clone selection and cost-effective manufacturing of life-saving immunotherapies.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers have engineered a monoclonal antibody that blocks allergic reactions against common pollen when applied inside the nose of mice, providing new hope for hay fever sufferers. The treatment, known as a 'molecular shield,' acts immediately and locally at the lining of the nose to prevent IgE antibodies from being activated.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Scientists have engineered a monoclonal antibody that protects mice from a lethal dose of influenza A with sticky staying power. The new molecule combines specificity and broad binding capacity, adhering to the lung lining and blocking infection in mice.
A clinical trial is underway to assess the effectiveness of sipavibart, a long-acting monoclonal antibody, in treating Long COVID symptoms. The study aims to improve patients' health and restore them to full health.
The Swiss Memory Clinics network has released new national guidelines on the use of anti-amyloid monoclonal antibodies, such as Lecanemab and Donanemab, for treating Alzheimer's disease. The guidelines outline criteria for patient selection, biomarker confirmation, and infrastructure requirements to support safe treatment delivery.
A new collaboration aims to develop an affordable and accessible monoclonal antibody therapeutic for CCHFV, treating thousands globally. USAMRIID discovered the antibody in mice, and LifeArc is supporting development of a fully humanized antibody.
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
The study analyzed 54 U.S. studies and found no significant association with serious adverse events for oral antivirals like Paxlovid or monoclonal antibodies. Actemra was associated with infection and low white blood cell counts, while transfusions of convalescent plasma were linked to internal bleeding and blood clots.
Researchers have made significant discoveries about the role of GP38 in viral infections and pathogenesis, highlighting its potential as a target for vaccines and medical countermeasures. Non-neutralizing GP38-specific antibodies have shown protective efficacy against lethal challenge, reducing circulating GP38 and vascular leak.
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
Scientists at Sanford Burnham Prebys developed a new method of generating antibodies by fusing two immune system proteins, enabling the creation of stable monoclonal antibodies. This breakthrough has potential applications in diagnosing and monitoring diseases such as lupus and cancers.
Researchers at The Lundquist Institute have developed an antibody called VX-01 that targets the fungus Mucorales and prevents it from damaging human cells and blood vessels. Early tests show that VX-01 is safe and effective in fighting mucormycosis, a disease with high mortality rates among those with weakened immune systems.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
The NIH-funded clinical trial aims to evaluate the safety and ability of AV-1 to lessen symptoms in people suffering from dengue. The study will expose adult volunteers to a weakened strain of dengue virus and administer AV-1 at various doses.
Researchers developed a predictive tool using the Florey Dementia Index to forecast onset ages of mild cognitive impairment and Alzheimer's. The validated tool may help prioritize patients for disease-modifying treatments.
Researchers developed a gene therapy approach to treat chronic hypereosinophilia by delivering an anti-human eosinophil antibody via AAV-based gene therapy. The therapy successfully suppressed blood eosinophil levels in mice, showing promise as a potential treatment for the condition.
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
Researchers have developed a new generation of cell-penetrating antibodies that can target cancer cells and deliver therapeutic molecules directly into tumor cells. The 3E10 antibody shows great promise for treating cancers with defective DNA repair pathways.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
Researchers observed a 100% response rate on Phase Ib trial for patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis. Early intervention with ELA026 may provide meaningful clinical benefits for patients with few options.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
A clinical trial found that cetuximab was more effective than durvalumab in treating advanced squamous cell carcinoma of the head or neck, with a higher probability of being alive and free of disease at two years. Cetuximab's efficacy was similar whether or not the cancer was associated with HPV.
Researchers from Kyushu University have developed an antibody that targets and prevents the dysfunction of hepatocyte growth factor (HGF), a critical protein for skeletal muscle development, regeneration, and repair. The new antibody, 1H42F4N, blocked nitration of HGF and did not disrupt its activity.
Researchers identified a protein in mammals that welcomes arteriviruses into host cells to start an infection. The team also found that an existing monoclonal antibody protects cells from viral infection, providing potential therapeutic strategy.
A new study suggests that immunotherapy may be an effective treatment strategy for heart failure by blocking scar tissue formation and improving heart function. Researchers identified a type of fibroblast cell responsible for scar tissue and used a monoclonal antibody to reduce its formation, showing promising results in mouse models.
Monoclonal antibodies (mAbs) are developed using hybridoma technology, offering a drastic reduction in adverse reactions and interactions. Their cost has decreased with biosimilar antibodies, making them more accessible for treating various diseases.
A team of researchers at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections. The antibodies were found to interact with antigens on the bacterial surface and some act synergistically to neutralize the pathogen.
Researchers have developed an antibody that can identify Campylobacter jejuni and inhibit its growth, reducing pathogenicity. The antibody targets a multiprotein complex essential for the bacteria's energy production, making it a potential target for therapy and vaccination.
Scientists at WashU Medicine are developing strategies and tools to produce vaccines and antibody-based therapies for viruses from five understudied families. The effort aims to rapidly respond to potential future pandemics, with funding totaling $90M over three years.
A new monoclonal antibody drug has been developed to prevent infection with A. baumannii, a common cause of hospital-acquired infections. The treatment was shown to be effective in reducing bacterial load in mice, and could potentially become a powerful new weapon against antimicrobial resistance.
A new study published in JAMA Health Forum found that machine learning can be more effective than traditional methods for distributing scarce treatments to patients most vulnerable during a public health crisis. The model reduces expected hospitalizations by about 27 percent compared to actual and observed care.
The NIH has established a pandemic preparedness research network, ReVAMPP, to focus on high-priority pathogens with the potential to cause deadly diseases. The network will study viruses from families that have caused human disease for millennia and aim to develop safe and effective medical countermeasures.
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques. The researchers found that higher levels of a critical brain protein correlate equally well with cognitive benefits.
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
A clinical study in Birmingham has found that nipocalimab can improve the survival rate of unborn babies with rare fetal anaemia. The majority of pregnant patients who received nipocalimab gave birth at or after 32 weeks without needing an intrauterine transfusion, resulting in a perinatal survival rate of 92%.
A study published in the Journal of Clinical Immunology found alemtuzumab to be safe and effective in treating Asian patients with inborn errors of immunity after allogeneic hematopoietic cell transplantation. The drug was shown to improve overall survival rates, with 94.7% of patients surviving post-transplantation.
Crystallized monoclonal antibodies demonstrate improved viscosity levels, stability, and shelf-life under microgravity conditions. This process streamlines manufacturing and improves scalability for subcutaneous administration, offering greater patient convenience and compliance.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.